Vertex Pharmaceuticals (Brazil) Top Management

VRTX34 Stock  BRL 696.51  8.76  1.24%   
Vertex Pharmaceuticals employs about 4.8 K people. The company is managed by 29 executives with a total tenure of roughly 152 years, averaging almost 5.0 years of service per executive, having 165.52 employees per reported executive. Analysis of Vertex Pharmaceuticals' management performance can provide insight into the company performance.
Reshma Kewalramani  CEO
President, Chief Executive Officer, Director
Charles Wagner  President
Chief Financial Officer, Executive Vice President
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Vertex Stock refer to our How to Trade Vertex Stock guide.

Vertex Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Vertex Pharmaceuticals Workforce Comparison

Vertex Pharmaceuticals Incorporated is rated first in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 442,084. Vertex Pharmaceuticals claims roughly 4,800 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.49 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.49.

Vertex Pharmaceuticals Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Vertex Pharmaceuticals Price Series Summation is a cross summation of Vertex Pharmaceuticals price series and its benchmark/peer.

Vertex Pharmaceuticals Notable Stakeholders

A Vertex Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vertex Pharmaceuticals often face trade-offs trying to please all of them. Vertex Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vertex Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Reshma KewalramaniPresident, Chief Executive Officer, DirectorProfile
Charles WagnerChief Financial Officer, Executive Vice PresidentProfile
William YoungIndependent DirectorProfile
Michael PariniExecutive Vice President Chief Legal and Administrative OfficerProfile
Alan GarberIndependent DirectorProfile
Mike TirozziSVP OfficerProfile
Damian EsqChief VPProfile
Jeffrey MDEx ChairmanProfile
MD FASNPres CEOProfile
Stuart BScEx COOProfile
John GraySenior Vice President Genetic TherapiesProfile
Margaret McGlynnIndependent DirectorProfile
Diana McKenzieIndependent DirectorProfile
Sangeeta BhatiaIndependent DirectorProfile
Terrence KearneyIndependent DirectorProfile
Nia TatsisSenior Vice President Chief Regulatory OfficerProfile
Kristen AmbroseTax, AccountingProfile
Paul SilvaSenior Vice President ControllerProfile
David AltshulerExecutive Vice President - Global Research, Chief Scientific OfficerProfile
Amit SachdevExecutive Vice President Chief Regulatory Officer and Chief of Staff to the CEOProfile
Gerald BruceExecutive Vice President Commercial OperationsProfile
Ourania TatsisEx OfficerProfile
Bruce SachsCo-Lead Independent DirectorProfile
Susie LisaVP RelationsProfile
Lloyd CarneyIndependent DirectorProfile
Yuchun LeeIndependent DirectorProfile
Stuart ArbuckleExecutive Vice President Chief Commercial OfficerProfile
Carmen BozicExecutive Vice President - Global Medicines Development and Medical Affairs, Chief Medical OfficerProfile
Jeffrey LeidenExecutive Chairman of the BoardProfile

About Vertex Pharmaceuticals Management Performance

The success or failure of an entity such as Vertex Pharmaceuticals often depends on how effective the management is. Vertex Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vertex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vertex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 3400 people.
Please note, the presentation of Vertex Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vertex Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.

Vertex Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Vertex Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vertex Pharmaceuticals within its industry.

Vertex Pharmaceuticals Manpower Efficiency

Return on Vertex Pharmaceuticals Manpower

Revenue Per Employee1.9M
Revenue Per Executive308M
Net Income Per Employee692.1K
Net Income Per Executive114.6M

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Fundamental Analysis
View fundamental data based on most recent published financial statements
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world